NASDAQ:MURA Mural Oncology (MURA) Stock Price, News & Analysis $2.42 -0.04 (-1.63%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$2.46 +0.04 (+1.45%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Mural Oncology Stock (NASDAQ:MURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mural Oncology alerts:Sign Up Key Stats Today's Range$2.42▼$2.4650-Day Range$2.42▼$2.9852-Week Range$0.95▼$4.74Volume65,353 shsAverage Volume76,073 shsMarket Capitalization$41.79 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. Read More Mural Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreMURA MarketRank™: Mural Oncology scored higher than 68% of companies evaluated by MarketBeat, and ranked 331st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMural Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMural Oncology has received no research coverage in the past 90 days.Read more about Mural Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mural Oncology are expected to grow in the coming year, from ($7.54) to ($4.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mural Oncology is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mural Oncology is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMural Oncology has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mural Oncology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.50% of the float of Mural Oncology has been sold short.Short Interest Ratio / Days to CoverMural Oncology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mural Oncology has recently decreased by 9.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMural Oncology does not currently pay a dividend.Dividend GrowthMural Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.50% of the float of Mural Oncology has been sold short.Short Interest Ratio / Days to CoverMural Oncology has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mural Oncology has recently decreased by 9.40%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.18 News SentimentMural Oncology has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Mural Oncology this week, compared to 3 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mural Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,730.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Mural Oncology is held by insiders.Percentage Held by Institutions80.21% of the stock of Mural Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mural Oncology's insider trading history. Receive MURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mural Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address MURA Stock News HeadlinesCan Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?July 23 at 6:32 AM | finance.yahoo.comMinneapolis muralist honors Tuskegee airmenJuly 19, 2025 | msn.comTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that you don't want to take with your retirement savings. | Create New Advertiser (Ad)Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.deJuly 8, 2025 | finanznachrichten.deBuilding that features the PINK of Terre Haute wings mural to be demolishedJuly 4, 2025 | msn.com'Vibrancy': New murals proposed for Downtown Peoria parking decksJuly 3, 2025 | msn.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 16, 2025 | markets.businessinsider.comBlackRock discloses 1.64% stake in Mural OncologyJune 13, 2025 | investing.comSee More Headlines MURA Stock Analysis - Frequently Asked Questions How have MURA shares performed this year? Mural Oncology's stock was trading at $3.22 on January 1st, 2025. Since then, MURA stock has decreased by 24.8% and is now trading at $2.42. How were Mural Oncology's earnings last quarter? Mural Oncology PLC (NASDAQ:MURA) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($1.93) earnings per share for the quarter, topping the consensus estimate of ($2.12) by $0.19. How do I buy shares of Mural Oncology? Shares of MURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mural Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mural Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings5/14/2025Today7/25/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MURA Previous SymbolNASDAQ:MURA CIK1971543 Webwww.muraloncology.com Phone353-1-905-8020FaxN/AEmployees119Year FoundedN/APrice Target and Rating Average Price Target for Mural Oncology$12.00 High Price Target$18.00 Low Price Target$6.00 Potential Upside/Downside+395.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($7.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$128.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.39% Return on Assets-70.70% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book0.29Miscellaneous Outstanding Shares17,270,000Free Float16,889,000Market Cap$41.79 million OptionableOptionable Beta3.03 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:MURA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.